EICHORPublic-registry site landscape for NCT05536752, “QA102 Phase II Study in Subjects With Dry AMD”, a Dry Age-related Macular Degeneration study sponsored by Smilebiotek Zhuhai Limited. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05536752 (registry record) |
| Study title | QA102 Phase II Study in Subjects With Dry AMD |
| Official title | A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD) |
| Sponsor | Smilebiotek Zhuhai Limited |
| Condition(s) | Dry Age-related Macular Degeneration |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | QA102/Placebo, QA102, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05536752.
Eichor generates a preliminary site-risk snapshot for NCT05536752 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
